Shinmura Ken, Nagai Maiko, Tamaki Kayoko, Tani Masato, Bolli Roberto
Department of Internal Medicine, Keio University School of Medicine, Tokyo 160 - 8582, Japan.
Am J Physiol Heart Circ Physiol. 2002 Dec;283(6):H2534-43. doi: 10.1152/ajpheart.00209.2002. Epub 2002 Aug 8.
Opioids confer biphasic (early and late) cardioprotection against myocardial infarction by opening mitochondrial ATP-sensitive K(+) channels. It is unknown whether cyclooxygenase-2 (COX-2), which mediates ischemia-induced late preconditioning, also mediates opioid-induced cardioprotection. Isolated perfused rat hearts were subjected to 20 min of global ischemia followed by 20 min of reperfusion. BW-373U86 (BW), a delta-opioid receptor agonist, was administered 1, 12, or 24 h before death. Recovery of left ventricular developed pressure (LVDP) after ischemia-reperfusion improved when BW was administered 1 or 24 h before ischemia (control: 57 +/- 8, BW 1 h: 75 +/- 5, BW 24 h: 85 +/- 6%) but not when it was administered 12 h before (60 +/- 5%). Levels of 6-keto-PGF(1alpha) (a stable metabolite of PGI(2)) in coronary effluent after 20 min of reperfusion were higher with 24-h BW pretreatment than in controls (1,053 +/- 92 vs. 724 +/- 81 pg/ml), whereas 6-keto-PGF(1alpha) levels at baseline did not differ. Administration of a selective COX-2 inhibitor, NS-398, abolished the late phase of cardioprotection (recovery of LVDP, 53 +/- 8%) and attenuated the increase in PGI(2) (706 +/- 138 pg/ml) but did not block the early phase of cardioprotection. The selective COX-1 inhibitor SC-560 did not affect either phase of protection. Western immunoblotting revealed upregulation of PGI(2) synthase protein 24 h after BW administration without changes in COX-1 and COX-2 protein levels. In conclusion, the late (but not the early) phase of delta-opioid receptor-induced preconditioning is mediated by COX-2. A functional coupling between COX-2 and upregulated PGI(2) synthase appears to underlie this cardioprotective phenomenon in the rat.
阿片类药物通过开放线粒体ATP敏感性钾通道对心肌梗死具有双相(早期和晚期)心脏保护作用。介导缺血诱导的晚期预处理的环氧化酶-2(COX-2)是否也介导阿片类药物诱导的心脏保护作用尚不清楚。将离体灌注的大鼠心脏进行20分钟的全心缺血,随后再灌注20分钟。在处死前1、12或24小时给予δ-阿片受体激动剂BW-373U86(BW)。当在缺血前1或24小时给予BW时,缺血再灌注后左心室舒张末压(LVDP)的恢复得到改善(对照组:57±8,BW 1小时:75±5,BW 24小时:85±6%),但在缺血前12小时给予时则未改善(60±5%)。再灌注20分钟后冠状动脉流出液中6-酮-PGF(1α)(PGI(2)的稳定代谢产物)水平在24小时BW预处理后高于对照组(1053±92对724±81 pg/ml),而基线时6-酮-PGF(1α)水平无差异。给予选择性COX-2抑制剂NS-398消除了心脏保护的晚期阶段(LVDP恢复,53±8%)并减弱了PGI(2)的增加(706±138 pg/ml),但未阻断心脏保护的早期阶段。选择性COX-1抑制剂SC-560对两个保护阶段均无影响。蛋白质免疫印迹显示BW给药24小时后PGI(2)合酶蛋白上调,而COX-1和COX-2蛋白水平无变化。总之,δ-阿片受体诱导的预处理的晚期(而非早期)阶段由COX-2介导。COX-2与上调的PGI(2)合酶之间的功能偶联似乎是大鼠这种心脏保护现象的基础。